Introduction
Methods
Participants
Procedure
Instruments
Sociodemographic and clinical characteristics
Fear of cancer recurrence/progression
Health-related quality of life
Psychological distress
Statistical analyses
Results
Sample characteristics
Total | Low FCR | High FCR |
p value | |
---|---|---|---|---|
N = 73 |
N = 28 |
N = 45 | ||
n (%)a
|
n (%)b
|
n (%)c
| ||
Gender | 0.12 | |||
Male | 36 (49%) | 17 (61%) | 19 (42%) | |
Female | 37 (51%) | 11 (39%) | 26 (58%) | |
Age at diagnosis (years) | 27.4 (4.6) | 26.3 (4.9) | 28.0 (4.4) | 0.12 |
Time since cancer diagnosis (years) | 1.9 (2.6) | 1.9 (3.6) | 1.9 (1.9) | 0.94 |
Tumor type | 0.53 | |||
Testicular cancer | 25 (34%) | 13 (46%) | 12 (27%) | |
Breast cancer | 11 (15%) | 2 (7%) | 9 (20%) | |
Sarcoma | 9 (12%) | 4 (14%) | 5 (11%) | |
Lymphoma | 8 (11%) | 2 (7%) | 6 (13%) | |
Gynecological | 7 (10%) | 3 (11%) | 4 (9%) | |
Melanoma | 2 (3%) | 0 (0%) | 2 (4%) | |
Leukemia | 2 (3%) | 1 (4%) | 1 (2%) | |
Other | 9(12%) | 3 (11%) | 6 (13%) | |
Stage | 0.15 | |||
NA | 8 (11%) | 5 (18%) | 3 (7%) | |
Stage 1 | 12 (16%) | 3 (11%) | 9 (20%) | |
Stage 2 | 23 (32%) | 11 (39%) | 12 (27%) | |
Stage 3 | 11 (15%) | 1 (4%) | 10 (22%) | |
Stage 4 | 13 (18%) | 5 (18%) | 8 (18%) | |
Unknown | 6 (8%) | 3 (11%) | 3 (7%) | |
Treatment status | 0.69 | |||
On | 17 (24%) | 6 (21%) | 11 (26%) | |
Off | 54 (76%) | 22 (79%) | 32 (74%) | |
Treatment type (yes) | ||||
Surgery | 61 (84%) | 24 (86%) | 37 (82%) | 0.70 |
Chemotherapy | 63 (86%) | 25 (89%) | 38 (84%) | 0.56 |
Radiotherapy | 20 (27%) | 5 (18%) | 15 (33%) | 0.15 |
Immunotherapy | 9 (12%) | 0 (0%) | 9 (20%) | 0.01 |
Hormonal therapy | 6 (8%) | 1 (4%) | 5 (11%) | 0.25 |
Partner | 0.51 | |||
Yes | 52 (72%) | 19 (68%) | 33 (75%) | |
No | 20 (28%) | 9 (32%) | 11 (25%) | |
Children | 0.49 | |||
Yes | 24 (33%) | 8 (29%) | 16 (36%) | |
No | 48 (67%) | 20 (71%) | 28 (64%) | |
Living situation | 0.13 | |||
With parents | 12 (17%) | 7 (25%) | 5 (11%) | |
On own | 19 (26%) | 9 (32%) | 10 (23%) | |
With partner | 41 (57%) | 12 (43%) | 29 (66%) | |
Highest completed education | 0.58 | |||
Low | 1 (1%) | 0 (0%) | 1 (2%) | |
Intermediate | 32 (44%) | 14 (50%) | 18 (41%) | |
High | 39 (54%) | 14 (50%) | 25 (57%) | |
Employed or studying | 0.91 | |||
Yes | 63 (86%) | 24 (86%) | 39 (87%) | |
No | 10 (14%) | 4 (14%) | 6 (13%) |
Prevalence FCR
Author year | Sample characteristics n, cancer type, stages (localized, metastatic, mixed) | Age | Treatment status | Mean CWS (SD) | Results of tests comparing means with present sample | % scoring above diagnostic cutoff (≥ 14) | Results of tests comparing % above cutoff with present sample |
---|---|---|---|---|---|---|---|
Custers, 2014 [17] |
N = 194 patients with breast cancer treated with curative intents and disease-free at time study | Age at time of study: 57.0 (SD, 10.2) years (range, 30–88 years) | Completed hospital-based treatments Time since diagnosis (years): mean 4.2, range 1–11; SD 2.3 | 13.4 (3.9) |
t = 2.78 mean difference = 1.49 p = 0.007 95% CI 0.42–2.56 | 31% | Difference = 31% (95% CI = 19–45%)
X
2 = 22.81; p = < 0.001 |
Custers 2016 [19] |
N = 76 patients with colorectal cancer treated with curative intents and disease-free at time study | Age at time of study: median 67.3, range = 41–88 | Treatment status not reported Time since diagnosis: 1.3–9.2 years post-surgery | 12.5 (4.0) |
t = 4.46 mean difference = 2.39 p = 0.002 95% CI 1.32–3.46 | 38% | Difference = 24% (95% CI = 9–41%)
X
2 = 9.20; p = 0.002 |
Custers 2016 [20] |
N = 54 patients with localized or metastatic gastrointestinal stromal tumors | Age at time of study: median 63.3; range 21–84 | 61% receiving active TKI treatment Time since diagnosis (years): median 3.9; range 0.5–17 | 14.5 (5.2) |
t = 0.728 mean difference = 0.39 p = 0.47 95% CI:− 0.68 to 1.46 | 52% | Difference = 10% (95% CI = − 6 to 28%)
X
2 = 1.59; p = 0.21 |
Van de Wal, 2016 [18] |
N = 283 patients with localized prostate cancer treated with curative intent | Age at time of study: median 70.0 (range 54–89) | Completed all hospital-based treatments Time since diagnosis(years): median 7.9; range 0.9–20 | 12.0 (3.7) |
t = 5.39 mean difference = 2.89 p = < 0.001 95% CI 1.82–3.96 | 36% | Difference = 27% (95% CI = 15–39%)
X
2 = 17.38; p = < 0.001 |
Correlates of high FCR
Association between high FCR, HRQoL, and psychological distress
Total
N = 73 | Low FCR
N = 28 | High FCR
N = 45 |
T value |
p value | |
---|---|---|---|---|---|
Quality of life for cancer survivors | |||||
Physical functioning | 7.5 (1.6) | 7.8 (1.7) | 7.4 (1.4) | 1.1 | 0.28 |
Psychological functioning | 5.8 (1.5) | 6.8 (1.1) | 5.1 (1.4) | 5.1 | < 0.01a
|
Social functioning | 5.2 (1.4) | 5.9 (1.4) | 4.8 (1.2) | 3.6 | < 0.01a
|
Religious functioning | 3.9 (1.2) | 4.1 (1.3) | 3.7 (1.3) | 1.3 | 0.20 |
Total | 5.7 (1.1) | 6.3 (1.0) | 5.3 (1.0) | 4.5 | < 0.01a
|
HADS | |||||
Anxiety | 6.3 (3.9) | 4.4 (3.0) | 7.5 (3.9) | − 3.5 | < 0.01a
|
Depression | 4.1 (3.5) | 3.2 (3.3) | 4.7 (3.5) | − 1.8 | 0.08 |
Total psychological distress | 10.4 (6.6) | 7.6 (5.7) | 12.2 (6.6) | − 3.0 | < 0.01a
|